- Home
- RGC vs LCTX Comparison
RGC vs LCTX Comparison
Compare RGC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- LCTX
- Stock Information
- Founded
- RGC 2014
- LCTX 1990
- Country
- RGC Hong Kong
- LCTX United States
- Employees
- RGC N/A
- LCTX N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RGC Health Care
- LCTX Health Care
- Exchange
- RGC Nasdaq
- LCTX Nasdaq
- Market Cap
- RGC 171.1M
- LCTX 165.6M
- IPO Year
- RGC 2021
- LCTX N/A
- Fundamental
- Price
- RGC $6.12
- LCTX $0.88
- Analyst Decision
- RGC
- LCTX Strong Buy
- Analyst Count
- RGC 0
- LCTX 3
- Target Price
- RGC N/A
- LCTX $5.67
- AVG Volume (30 Days)
- RGC 35.0K
- LCTX 416.6K
- Earning Date
- RGC 10-25-2024
- LCTX 08-08-2024
- Dividend Yield
- RGC N/A
- LCTX N/A
- EPS Growth
- RGC N/A
- LCTX N/A
- EPS
- RGC N/A
- LCTX N/A
- Revenue
- RGC N/A
- LCTX $6,186,000.00
- Revenue This Year
- RGC N/A
- LCTX N/A
- Revenue Next Year
- RGC N/A
- LCTX $119.00
- P/E Ratio
- RGC N/A
- LCTX N/A
- Revenue Growth
- RGC N/A
- LCTX N/A
- 52 Week Low
- RGC $3.03
- LCTX $0.77
- 52 Week High
- RGC $32.44
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- RGC 41.60
- LCTX 47.00
- Support Level
- RGC $5.52
- LCTX $0.83
- Resistance Level
- RGC $6.57
- LCTX $0.92
- Average True Range (ATR)
- RGC 0.82
- LCTX 0.06
- MACD
- RGC -0.26
- LCTX 0.00
- Stochastic Oscillator
- RGC 16.09
- LCTX 36.08
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.